Published in Drug Week, December 14th, 2001
The findings were presented in November 2001 at the American Heart Association (AHA) Scientific Sessions by Roberto Latini MD, head of the laboratory of cardiovascular pharmacology, Istituto di Ricerche Farmacologiche, Mario Negri, Milano, Italy. The Valsartan Heart Failure Trial (Val-HeFT) was sponsored by Novartis Pharma AG.
"BNP levels have been shown to correlate with cardiac...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.